| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44042872 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44042875 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44035325 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44051683 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | APP |
|---|---|
| DrugBank ID | DB14580 |
| Drug Name | Lecanemab |
| Target ID | BE0003392 |
| UniProt ID | P05067 |
| Regulation Type | binder |
| PubMed IDs | 27048170; 33865446 |
| Citations | Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L: Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. 2016 Apr 6;8(1):14. doi: 10.1186/s13195-016-0181-2.@@Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8. |
| Groups | Approved; Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
